CJC-1295 (No DAC) + Ipamorelin 10MG

Product Overview

CJC-1295 (No DAC) + Ipamorelin 10MG is a two-component lyophilised blend containing CJC-1295 (No DAC) and Ipamorelin, supplied as white to off-white lyophilised powder in a 10mg catalogue presentation (SKU CP10). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

The two components are associated with different points in growth-hormone secretagogue research: a GHRH-receptor analogue and a ghrelin-receptor agonist. Individual-component literature does not validate the combined formulation.

Identity and Specifications

• Product: CJC-1295 (No DAC) + Ipamorelin 10MG
• SKU: CP10
• Format: White to off-white lyophilised powder
• Synonyms: Modified GRF (1-29) + Ipamorelin, CJC-1295 No DAC + Ipamorelin
• Composition: CJC-1295 (No DAC) 5mg + Ipamorelin 5mg
• Component verification: See linked Janoshik COA
• Total amount: 10mg

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• dual-pathway endocrine signalling models
• GHRH- and ghrelin-receptor assay design
• component identity and ratio verification
• combined-formulation stability and compatibility testing

Evidence Quality and Limitations

Evidence for the individual components is mainly pharmacological and early-stage. The blend itself requires product-specific analytical and method validation; additive or synergistic effects must not be assumed.

Storage and Handling

Before reconstitution: Keep the sealed lyophilised blend dry and protected from light at −20°C or below, subject to the batch-specific supplier documentation. Component references support frozen storage as supplied, but they do not establish stability of the combined CJC-1295 No DAC and Ipamorelin formulation.

After reconstitution: No reliable combined-formulation stability period has been verified. The short aqueous hold time reported for ipamorelin acetate cannot be transferred to this blend. Validate the solvent, concentration, pH, container, temperature and hold time for the complete formulation. Where the validated method supports frozen storage, use single-use aliquots and avoid vigorous agitation and repeated freeze–thaw cycles. Record the preparation and storage history.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• Component storage references: CJC-1295 No DAC insert and Ipamorelin acetate insert
• PubMed: Tetrasubstituted hGRF(1–29) and CJC-1295 development
• PubMed: Ipamorelin pharmacology
• PubMed: Review of growth hormone secretagogues

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.